Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Survey of activated FLT3 signaling in leukemia.

Gu TL, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi SP, Druker BJ, Heinrich MC, Rush J, Polakiewicz RD.

PLoS One. 2011 Apr 28;6(4):e19169. doi: 10.1371/journal.pone.0019169.

2.

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144. Epub 2010 Feb 16.

3.

Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.

Arora D, Stopp S, Böhmer SA, Schons J, Godfrey R, Masson K, Razumovskaya E, Rönnstrand L, Tänzer S, Bauer R, Böhmer FD, Müller JP.

J Biol Chem. 2011 Apr 1;286(13):10918-29. doi: 10.1074/jbc.M110.205021. Epub 2011 Jan 24.

4.

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017. Epub 2010 Apr 7.

PMID:
20380868
5.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
6.

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA.

Cancer Cell. 2002 Jun;1(5):421-32.

PMID:
12124172
7.

FLT3 mutations in canine acute lymphocytic leukemia.

Suter SE, Small GW, Seiser EL, Thomas R, Breen M, Richards KL.

BMC Cancer. 2011 Jan 27;11:38. doi: 10.1186/1471-2407-11-38.

8.

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.

Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ, Rassidakis GZ.

Mol Cancer. 2010 Nov 10;9:292. doi: 10.1186/1476-4598-9-292.

9.

Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.

Nakajima H, Shibata F, Kumagai H, Shimoda K, Kitamura T.

Int J Hematol. 2006 Jul;84(1):54-9.

PMID:
16867903
10.

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D.

Leukemia. 2002 Oct;16(10):2027-36.

11.

Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.

Gunawardane RN, Nepomuceno RR, Rooks AM, Hunt JP, Ricono JM, Belli B, Armstrong RC.

Mol Cancer Ther. 2013 Apr;12(4):438-47. doi: 10.1158/1535-7163.MCT-12-0305. Epub 2013 Feb 14.

12.

Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.

Yamamoto Y, Tsuzuki S, Akahori Y, Ukai Y, Sumitomo M, Murayama Y, Yamamoto K, Inaguma Y, Tokuda M, Abe A, Akatsuka Y, Emi N, Kurosawa Y.

Cancer Sci. 2012 Feb;103(2):350-9. doi: 10.1111/j.1349-7006.2011.02141.x. Epub 2011 Dec 5.

13.

Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.

Razumovskaya E, Masson K, Khan R, Bengtsson S, Rönnstrand L.

Exp Hematol. 2009 Aug;37(8):979-89. doi: 10.1016/j.exphem.2009.05.008. Epub 2009 May 27.

PMID:
19477218
14.

Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.

Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, Nolan GP, Gjertsen BT.

Blood. 2007 Mar 15;109(6):2589-96. Epub 2006 Nov 14.

15.

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.

Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, Burnett A, Rowntree C.

Br J Haematol. 2008 May;141(4):483-93. doi: 10.1111/j.1365-2141.2008.07053.x. Epub 2008 Mar 27.

PMID:
18373709
16.

CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.

Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.

Clin Cancer Res. 2005 Jul 15;11(14):5281-91.

17.

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.

Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. German.

PMID:
12397548
18.
19.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D.

Blood. 2002 Jun 1;99(11):3885-91.

20.

Supplemental Content

Support Center